All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ECHELON-2 trial: response by CD30 expression

Ranjana Advani speaks about how CD30 expression levels in patients with T-cell lymphoma (AITL, PTCL-NOS) would affect response to brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone.

Dr. Advani explains that the subset analysis was looking at levels of expression of CD30 and whether it correlated with outcomes. For the study entry, 10% or greater expression was required, as determined by immunohistochemistry (ICH).

ECHELON-2 trial: response by CD30 expression

Share: